AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Case-Based Dermatomyositis

Description

The focused presentation detailed dermatomyositis (DM), an autoimmune disorder affecting both adults and children, emphasizing its clinical features, such as characteristic skin findings and muscle involvement. The speaker advocated for a case-based approach to understanding DM, including recognition of patterns in symptoms and antibody correlations. The discussion included demographic insights highlighting a female predominance and associations with malignancies, particularly in adults. Significant cases of juvenile DM were presented, illustrating how it can manifest acutely in children without malignancy concerns but with risks like vasculopathy, which can lead to serious complications such as bowel ischemia. Additionally, notable adult cases illustrated unique presentations, especially those related to specific antibodies like MDA-5 and TIF-1 gamma, highlighting their links to interstitial lung disease and malignancy respectively. The talk also addressed modern treatment options, including traditional therapies like steroids and methotrexate, and emerging treatments involving JAK inhibitors and new immunotherapies. The speaker insisted that while antibodies can guide prognosis, they are not definitive, with many patients presenting without identifiable antibodies. This comprehensive overview aimed to enhance the audience's understanding of DM through case discussions, ultimately highlighting the necessity for both medical vigilance and individualized patient care.

View more

Conclusions

  • Dermatomyositis is an autoimmune disease that typically occurs in genetically susceptible individuals and can be triggered by various environmental factors.
  • The likelihood of developing dermatomyositis varies among different age groups, with peaks in juvenile and middle-aged populations, and a higher prevalence in women and African American patients.
  • Autoantibodies associated with dermatomyositis can help inform prognosis and treatment strategies, though they are not definitive indicators for all patients.
  • Juvenile dermatomyositis can represent a medical emergency due to potential vasculopathy, leading to significant morbidity and mortality.
  • The relationship between dermatomyositis and malignancy varies based on ethnicity and geographical location, with a notable association in older patients with specific autoantibodies like TIF-1.
  • Treatment strategies often include immunosuppressive therapies such as prednisone, methotrexate, and newer biologics and JAK inhibitors, which can improve disease outcomes in some patients.
  • Management of dermatomyositis requires a thorough understanding of its clinical features and potential complications to optimize patient care and reduce risks.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.
  • Cheeti A, Panginikkod S. Dermatomyositis And Polymyositis. StatPearls. Treasure Island (FL) 2019.
  • Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30.
  • DeWane et al. Dermatomyositis: Clinical features and pathogenesis. JAAD CME 2020.
  • Bogdanov I et al. Dermatomyositis: Current Concepts. Clinics in Dermatology 2019; 36(4):450-458.
  • Kim H, Huber A, Kim S. Updates on Juvenile Dermatomyositis from the last decade: Classification to Outcomes. Rheum Dis Clinics of North America 2021;47(4).
  • Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41(1):22-26.
  • Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585-3592.
  • Gorouhi F, Kiuru M, Silverstein M, Emami-Naeini P, Park SS, Tartar D. The pulseless patient: Profound vasculopathy as the presenting feature of fulminant dermatomyositis and response to therapy. JAAD Case Rep. 2019;5(2):176-179.
  • Park SS, Tartar D. The pulseless patient: Profound vasculopathy as the presenting feature of fulminant dermatomyositis and response to therapy. JAAD Case Rep. 2019 Feb; 5(2): 176-179. PMCID: PMC6357546, PMID: 30740501, doi: 10.1016/j.jdcr.2018.11.011.
  • Tartar DM, Chung L, Fiorentino DF. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol. 2018;36(4):508-524.
  • Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancermyositis connection. Arthritis Rheum. 2012;64:346-349.
  • Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with anti-transcriptional intermediary factor 1y antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449-455.
  • Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682-3689.
  • Meisterfeld S, Röber N, Conrad K, et al. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-y. Br J Dermatol. 2017;177:590-593.
  • Masiak A, Kulczycka J, Czuszyńska Z, et al. Clinical characteristics of patients with anti-TIF1-y antibodies. Reumatologia. 2016;54:14-18.
  • Goswami R, et al. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis. Autoimmunity Reviews, 2022.
  • Rogers A, et al. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken), 2017.
  • Selva-O'callaghan et al. Venous thromboembolism in patients with dermatomyositis and polymyositis. Clin Exp Rheum 2011; 846-9.
  • Chung et al. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb res 2014; 622-6.
  • Ladislau L, Suarez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609-1621.
  • Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol. 2016;152(8):944-945.
  • Hornig J, Weinhage T, Schmidt LH, et al. [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]. Z Rheumatol. 2018;77(10):952-957.
  • Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114-2119.
  • Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537-2538.
  • Guo X, Higgs BW, Rebelatto M, et al. Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford). 2014;53(4):686-695.
  • Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256-262.
  • Tjarnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77(1):55-62.